晚期胰腺神经内分泌癌中对anlotinib的持续反应:一个病例报告
Yan Zhang1, Yanchun Wang1, Jingjing Wu2
1Department of Oncology, The 900th Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Fuzong Clinical College of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China.
Oncology letters
|February 22, 2024
概括
胰腺神经内分泌癌 (pNEC) 是罕见的. 一名患有转移性PNEC的患者在60个月以上的时间内存活下来,接受了以托波西德-西斯普拉丁化疗,随后接受了anlotinib,这表明了持续的反应.
科学领域:
- 在瘤学瘤学.
- 医学案例报告 病例报告
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰腺神经内分泌癌 (pNEC) 是一种具有侵略性的恶性瘤,治疗选择有限,预后不佳.
- 转移性PNEC通常具有很短的生存时间,平均为8-12个月.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
